Literature DB >> 15235691

Serum levels of lipids and lipoproteins in Syrian patients with beta-thalassemia major.

Faizeh A Al-Quobaili1, Imad E Abou Asali.   

Abstract

OBJECTIVE: Evaluation serum lipids, lipoprotein (a), apolipoprotein A1, apolipoprotein B and total antioxidant status (TAS) in syrian patients with beta-thalassemia major.
METHODS: This study was carried out at Damascus University (Biochemical Laboratories of Medicine and Pharmacy Colleges), Syria between May 2002 and April 2003. This study included 30 patients with beta-thalassemia major, aged between 1.5 and 16-years. All patients had undergone regular blood transfusions and iron chelation therapy (through thalassemia center, Damascus, Syria); also 30 control subjects matched for age were studied. Serum total cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride, apolipoprotein A1 (apo A1), apolipoprotein B (apo B), lipoprotein (a) [Lp(a)] and total antioxidant status (TAS) were determined. Blood samples were withdrawn after at least 12-hours of patients fasting and before the blood transfusion.
RESULTS: beta-thalassemia major patients had significantly lower total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and lower density lipoprotein (LDL-C) compared with control (P<0.0001, P<0.0001, P<0.003). While serum triglyceride (TG) and lipoprotein (a) [Lp(a)] levels were higher in b-thalassemia patients than in controls (P<0.0001). The reduction was significant (P<0.0001), in apolipoprotein A1 (apo A1) but not significant (P=0.537) in apo B serum levels, in patients compared to control subjects. Total antioxidant status (TAS) values were lower in beta-thalassemia major patients than in controls.
CONCLUSION: The results might suggest that beta- thalassemia may represent an interesting metabolic model: anemia, an activated macrophage system and defective liver function seem interrelated to the final serum lipoprotein pattern. This suggests that antioxidants counteract lipid peroxidation processes and have a protective effect against oxidative damage of red cells of beta-thalassemia patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15235691

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  8 in total

1.  L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin.

Authors:  Michele Malaguarnera; Marco Vacante; Maria Giordano; Massimo Motta; Gaetano Bertino; Manuela Pennisi; Sergio Neri; Mariano Malaguarnera; Giovanni Li Volti; Fabio Galvano
Journal:  World J Gastroenterol       Date:  2011-10-21       Impact factor: 5.742

2.  Plasma lipids and lipoproteins in children and young adults with major β-thalassemia from western Iran: influence of genotype.

Authors:  Hamid Madani; Zohreh Rahimi; Mohammad Manavi-Shad; Hadi Mozafari; Reza Akramipour; Asad Vaisi-Raygani; Mansour Rezaei; Shohreh Malek-Khosravi; Ebrahim Shakiba; Abbas Parsian
Journal:  Mol Biol Rep       Date:  2010-11-18       Impact factor: 2.316

3.  Iron loading impairs lipoprotein lipase activity and promotes hypertriglyceridemia.

Authors:  Jonghan Kim; Xuming Jia; Peter D Buckett; Sihao Liu; Chih-Hao Lee; Marianne Wessling-Resnick
Journal:  FASEB J       Date:  2012-12-14       Impact factor: 5.191

4.  Lipid Profiles and Hepatitis C Viral Markers in HCV-Infected Thalassemic Patients.

Authors:  Seyed-Moayed Alavian; Seyyed Mohammad Miri; Seyed-Vahid Tabatabaei; Maryam Keshvari; Bita Behnava; Pegah Karimi Elizee; Nastaran Mahboobi; Kamran Bagheri Lankarani
Journal:  Gut Liver       Date:  2011-08-18       Impact factor: 4.519

5.  Serum lipid profiles in patients with beta-thalassemia major and intermedia in southern Iran.

Authors:  Sezaneh Haghpanah; Maryam Davani; Behrang Samadi; Afsaneh Ashrafi; Mehran Karimi
Journal:  J Res Med Sci       Date:  2010-05       Impact factor: 1.852

6.  Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker.

Authors:  Laila M Sherief; Osama Dawood; Adel Ali; Hanan S Sherbiny; Naglaa M Kamal; Mohamed Elshanshory; Osama Abd Alazez; Mohamed Abd Alhady; Mohamed Nour; Wesam A Mokhtar
Journal:  BMC Pediatr       Date:  2017-03-09       Impact factor: 2.125

7.  Reflection of treatment proficiency of hydroxyurea treated β-thalassemia serum samples through nuclear magnetic resonance based metabonomics.

Authors:  Ayesha Khalid; Amna Jabbar Siddiqui; Saqib Hussain Ansari; Syed Ghulam Musharraf
Journal:  Sci Rep       Date:  2019-02-14       Impact factor: 4.379

8.  Hematological and biochemical status of Beta-thalassemia major patients in Bangladesh: A comparative analysis.

Authors:  Md Fazlul Karim; Md Ismail; Akm Mahbub Hasan; Hossain Uddin Shekhar
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.